<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">It is critical for CoV vaccines to induce robust humoral and cellular immunities. Previous studies indicated that the level of serum neutralizing antibody is correlated inversely with virus titers in the lungs, which effectively increased the survival rate of the vaccine host
 <xref rid="bib40" ref-type="bibr">40</xref>, 
 <xref rid="bib41" ref-type="bibr">41</xref>, 
 <xref rid="bib42" ref-type="bibr">42</xref>. Production of high titer neutralizing antibodies can block MERS-CoV replication in the lungs of vaccinated mice (
 <xref rid="fig2" ref-type="fig">Fig. 2</xref> ), confirming the importance of neutralizing antibody in fighting virus infection
 <xref rid="bib42" ref-type="bibr">
  <sup>42</sup>
 </xref>. Similarly, the importance of T-cell responses against CoV infections was also highlighted in many studies
 <xref rid="bib43" ref-type="bibr">43</xref>, 
 <xref rid="bib44" ref-type="bibr">44</xref>, 
 <xref rid="bib45" ref-type="bibr">45</xref>, 
 <xref rid="bib46" ref-type="bibr">46</xref>. For example, depletion of CD4
 <sup>+</sup> and CD8
 <sup>+</sup> T cells in mice prior to challenge by SARS-CoV resulted in decreased survival rates to 35% and 45%, respectively (
 <xref rid="fig3" ref-type="fig">Fig. 3</xref> )
 <xref rid="bib45" ref-type="bibr">
  <sup>45</sup>
 </xref>. Interestingly, virus-specific memory T cells but not neutralizing antibodies could be detected 6 years after infection in SARS survivors, suggesting memory T cell responses may provide broad and long-term protection against SARS-CoV infection
 <xref rid="bib46" ref-type="bibr">
  <sup>46</sup>
 </xref>. In general, both neutralizing antibody levels and T cell responses should be considered in current CoV vaccination strategies.
</p>
